title: Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute.
abstract: BACKGROUND
  In Japan, mass screening for neuroblastoma has been performed at 6 months of age to improve the prognosis of this condition for more than 20 years. In recent years, most neuroblastomas detected by mass screening were considered to have favorable biological features and sometimes tend to regress spontaneously.
  
  
  METHODS
  The authors established non-treated observation criteria in 1997 and criteria for observation of residual tumor after first-line chemotherapy in 1999, and have made an effort to reduce the intensity of medical treatment for neuroblastoma. The authors examined outcomes of 79 patients who were found in the Shizuoka neuroblastoma mass screening at 6 months of age and who received medical treatment or underwent observation in Shizuoka Children's Hospital, Shizuoka, Japan, between December 1981 and December 2004.
  
  
  RESULTS
  A total of 77 patients survived but the remaining two patients died from complications of medical treatment. None of the patients died due to progression of neuroblastoma. In the cases, non-treated observation was performed in 17. Of those, 12 patients are now under non-treated observation. Of their tumors, two have disappeared, nine have become smaller and another one has not change in size. Observation of residual tumor after first-line chemotherapy was performed in 15 cases, and three disappeared and the other 12 cases became smaller. Medical treatment-related complications were observed in 20 of 67 patients who received medical treatment, and 18 of the 20 patients were seen before establishing non-treated observation criteria.
  
  
  CONCLUSIONS
  Non-treated observation and observation of residual tumor after first-line chemotherapy were useful to reduce medical treatment-related complications.
authors.affiliation: Department of Hematology, Shizuoka Children's Hospital, Shizuoka, Japan. nnisio@sch.pref.shizuoka.jp
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Nishio
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Mimaya
authors.forename: Taemi
authors.initials: T
authors.lastname: Nara
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Takashima
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Horikoshi
authors.forename: Naoto
authors.initials: N
authors.lastname: Urushihara
authors.forename: Shiro
authors.initials: S
authors.lastname: Hasegawa
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Aoki
authors.forename: Minoru
authors.initials: M
authors.lastname: Hamasaki
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000175:diagnosis / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000652:urine; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D007223:Infant; D007564:Japan / Q000453:epidemiology; D008403:Mass Screening; D008479:Mediastinal Neoplasms / Q000175:diagnosis / Q000628:therapy; D009365:Neoplasm Regression, Spontaneous; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy* / Q000652:urine; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014642:Vanilmandelic Acid / Q000652:urine
chemical_list: D014408:Biomarkers, Tumor; D014642:Vanilmandelic Acid; D006719:Homovanillic Acid